Sangamo Therapeutics Reports Recent Business Highlights and ...
Sangamo Therapeutics, Inc. (SGMO) Stock Price, Quote & News
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2024 FINANCIAL RESULTS. 6 months ago - Business ...
Sangamo Therapeutics (SGMO) News Today - MarketBeat
(NASDAQ:SGMO - Get Free Report) was the target of unusually large options trading on Tuesday. Stock investors acquired 6,620 call options on the company. This ...
News Releases | Investor Relations | Sangamo Therapeutics, Inc.
Investors & Media · Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare Conference · Sangamo Therapeutics Reports Recent Business ...
Sangamo Therapeutics Announces Q2 2024 Results and Business ...
As of June 30, 2024, Sangamo held $27.8 million in cash and cash equivalents, down from $81 million at the end of 2023. The recent Genentech ...
Michel Doepke on X: "$SGMO Reports Recent Business Highlights ...
$SGMO Reports Recent Business Highlights and Third Quarter 2024 Financial Results. $39.2M Cash. ... Sangamo Therapeutics Reports Recent Business ...
News of SANGAMO THERAPEUTICS INC(NASDAQ:SGMO) stock
3 months ago - Sangamo Therapeutics, Inc. Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results. News Image. 3 ...
Sangamo Therapeutics Stock News (SGMO) - Page 2 - Public.com
Latest Sangamo Therapeutics News: View SGMO news and ... Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results.
Sangamo Loses Collaborators on Neurological ... - CGTLive®
Biogen and Novartis terminated collaborations with the company that first initiated in 2020. Advertisement. Sangamo Therapeutics has seen 2 of ...
SGMO - Sangamo Therapeutics Inc Stock Price and Quote
Aug-04-22 05:45PM · Sangamo Therapeutics (SGMO) Reports Q2 Loss, Tops Revenue Estimates. (Zacks) +9.01% ; 04:01PM · Sangamo Therapeutics Reports Recent Business ...
SGMO Sangamo Therapeutics, Inc. Stock Price & Overview
Over the last year, Sangamo Therapeutics, Inc.'s stock price has increased by 812.15%. Sangamo Therapeutics, Inc. is currently approximately $2.71 per share. Is ...
Sangamo Therapeutics Interview - United States Life Sciences 2023
Sangamo Therapeutics specializes in genomic medicine. We have various ongoing projects, such as Hemophilia A in partnership with Pfizer, a wholly-owned ...
Sangamo Therapeutics Reports Strong Q3 2024 Growth
Key financial highlights show a remarkable increase in revenue from $9.4 million to $49.4 million compared to the same period last year, ...
Sangamo Therapeutics (SGMO-Q) Stock Price and News
... Reports Preliminary First Quarter 2023 Financial Results. April 26, 2023 ... Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on ...
Sangamo Therapeutics, Inc. - SGMO - Financial Statement Analysis
Latest Headlines for Sangamo Therapeutics, Inc. · Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast · individual investors who own 55% ...
Sangamo Therapeutics Presents Recent Developments from ...
The Company is advancing Phase 1/2 clinical programs in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo ...
StockWatch: Phase III Data for Pfizer-Partnered Hemophilia A Gene ...
Sangamo stock soared this week after it joined Pfizer to report positive Phase III data for their hemophilia A gene therapy candidate.
Sangamo Therapeutics reports progress in gene therapies
However, the company is currently not profitable, with a negative P/E ratio of -2.88 over the last twelve months as of Q2 2024. This aligns with ...
Sangamo Therapeutics Reports Strong Q3 2024 Growth - TipRanks
Key financial highlights show a remarkable increase in revenue from $9.4 million to $49.4 million compared to the same period last year, ...
Sangamo Therapeutics Inc, GBY:BER summary - FT.com
Latest Sangamo Therapeutics Inc (GBY:BER) share price ... Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results ...
News Releases | Investor Relations | Sangamo Therapeutics, Inc.
Investors & Media · Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results · Sangamo Therapeutics ...